Data of the present study raise the intriguing prospect that NOX4 could represent an attractive target for treatment of disorders associated with deregulation of cAMP signaling in the CCD, such as nephrogenic diabetes insipidus (NDI) and polycystic kidney disease (PKD). This evidence concerns the gene NOX4 and nephrogenic diabetes insipidus.